Organization Profile

You just read:

ALLY 3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin Demonstrates High Cure Rates in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis

News provided by

Bristol-Myers Squibb Canada

Nov 16, 2015, 07:00 ET